Timo Soeterik

23 General Introduction and Thesis Outline REFERENCES 1. IKNL. Incidentie prostaatkanker. https:// www.iknl.nl/kankersoorten/prostaatkanker/ registratie/ incidentie. Published 2019. Accessed December 21, 2020. 2. RIVM. Demografische prognose ziekten 2015- 2040. https://www.volksgezondheidenzorg. info/ onderwerp/demografische-prognose- ziekten-en-aandoeningen/toel ichting- demografische-prognose. Published 2017. Accessed December 21, 2020. 3. Mellinger GT. Carcinoma of the Prostate. Lancet . 1963;83:94-105. 4. Hermanek P, Sobin L. International Union Against Cancer. TNM Classification of Malignant Tumours, ed 4. 1987. 5. Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin . 2017;67:245-253. 6. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother reports . 1966;50:125-128. 7. Gleason D, Mellinger G, The Veterans Administratoin Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol . 1974;111:58-64. 8. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J Surg Pathol . 2016;40:244-252. 9. Gutman AB, Gutman EB. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Investig . 1938;17:473-478. 10. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol . 1979;17:159-163. 11. Delaere KPJ, Van Dieijen-Visser MP, Gijzen AHJ, Brombacher PJ. Is prostate-specific antigen the most useful marker for screening in prostate cancer? Am J Clin Oncol . 1988; Suppl 2:S65-7. 12. Powell CS, Fielding AM, Rosser K, Ames AC, Vaughton KC. Prostate Specific Antigen—a Screening Test for Prostatic Cancer? Br J Urol . 1989;64:504-506. 13. Stamey TA, Yang N, Hay AR, Mcneal J, Freiha FS, Redwine E. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate. N Engl J Med . 1987;317:909-916. 14. Potosky AI, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA J AmMed Assoc . 1995;273:548-552. 15. Schroder FH, Hugosson J, Roobol MJ, et al. The European Randomized Study of Screening for Prostate Cancer – Prostate Cancer Mortality at 13 Years of Follow-up. Lancet . 2014;384:2027-2035. 16. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst . 2003;95:868-878. 17. Mottet N, Bellmunt J, Briers E, et al. EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam; 2020. 18. Freedland SJ, Hotaling JM, Fitzsimons NJ, et al. PSA in the New Millennium: A Powerful Predictor of Prostate Cancer Prognosis and Radical Prostatectomy Outcomes - Results from the SEARCH Database. Eur Urol . 2008;53:758-766. 19. D’Amico A V., Whittington R, Bruce Malkowicz S, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J AmMed Assoc . 1998;280:969-974. 20. Vickers AJ, Fearn P, Scardino PT, Kattan MW. Why Can’t Nomograms Be More Like Netflix? Urology . 2010;75:511-513. 1